Results 141 to 150 of about 101,059 (295)

PTH-like Peptides

open access: yes, 2006
The present invention relates to peptides that are parathyroid hormone (PTH) analogs, useful for the treatment of hypoparathyroidism and diseases characterized by bone mass reduction, such as osteoporosis, and for stimulating bone repair or favoring the ...
MAMMI, STEFANO   +10 more
core  

Step2Motion: Locomotion Reconstruction from Pressure Sensing Insoles

open access: yesComputer Graphics Forum, EarlyView.
Abstract Human motion is fundamentally driven by continuous physical interaction with the environment. Whether walking, running, or simply standing, the forces exchanged between our feet and the ground provide crucial insights for understanding and reconstructing human movement. Recent advances in wearable insole devices offer a compelling solution for
J. L. Ponton   +5 more
wiley   +1 more source

Scalable Computation of Topological Abstractions for Scalar Data

open access: yesComputer Graphics Forum, EarlyView.
Abstract Topological data analysis has become an important tool for large scale scalar data analysis and visualization, efficiently extracting the inherent structure and features of interest of the data. However, with growing dataset sizes and complexity, it is increasingly becoming infeasible to compute topological abstractions of interest in serial ...
M. Will   +6 more
wiley   +1 more source

PTH-related protein and Type 1 PTH receptor mRNA expression in ventricular myocardial hypertrophy

open access: yes, 2005
Background: The parathyroid hormone (PTH)-related protein (PTHrP) and Type 1 PTH receptor (PTH-1.R) bioregulation system exerts positive inotropic and chronotropic actions on myocardium in vivo, and it is implicated in cell-cell interactions, which can ...
Lembessis, P.   +5 more
core   +1 more source

Multisystem developmental abnormalities and insulin resistance in ADTKD‐HNF1B with the p.E105K variant: A clinical conundrum

open access: yesDiabetic Medicine, EarlyView.
Abstract Aims HNF1B variants cause autosomal dominant tubulointerstitial kidney disease (ADTKD‐HNF1B), but the phenotypic spectrum of variants of uncertain significance (VUS) remains incompletely defined. We aimed to characterise the multisystem phenotype associated with the HNF1B p.E105K variant and to examine the mechanism underlying insulin ...
YunZe Wang   +5 more
wiley   +1 more source

Additive Glucagonotropic and Insulinotropic Effects of Glucose‐Dependent Insulinotropic Polypeptide and Alanine in Fasted Healthy Men

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims/Hypothesis Glucose‐dependent insulinotropic polypeptide (GIP) is a bidirectional glucose‐stabilising hormone potentiating insulin secretion at high glucose levels and glucagon secretion during normal‐to‐low plasma glucose levels. Preclinically, GIP and the amino acid alanine show synergistic glucagonotropic effects at low glucose levels ...
Julie Warnøe   +13 more
wiley   +1 more source

Novel targets in headache: A narrative review

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background This narrative review summarizes novel applications for the use of calcitonin gene‐related peptide (CGRP)‐targeted therapies that go beyond migraine, the latest updates with respect to targeting pituitary adenylate cyclase‐activating peptide (PACAP) as therapeutic in migraine, as well as exploring other more recently ...
Adriana Della Pietra   +5 more
wiley   +1 more source

The Impact of Surgical Technique on Post-Tonsillectomy Hemorrhage-A Registry-Based Cohort Study. [PDF]

open access: yesLaryngoscope Investig Otolaryngol
Zahl SM   +3 more
europepmc   +1 more source

Evolution of PTH assays

open access: yes, 2017
PTH metabolism is complex and the circulating forms include the intact 1-84 molecule as well as several carboxyl-terminal fragments. The first generation of PTH assays included several types of competitive assays, with specificities that spanned carboxyl,
Vieira, Jose Gilberto H.   +2 more
core  

Denosumab discontinuation and fracture risk: getting the balance right

open access: yesInternal Medicine Journal, EarlyView.
Abstract Denosumab is a highly effective therapy for osteoporosis. Since its approval by the Therapeutic Goods Administration (TGA) in 2010, use of denosumab has surged across Australia, delivering substantial fracture‐prevention benefits to tens of thousands of patients. However, stopping denosumab may lead to acute loss of bone with an increased risk
Albert S. Kim, Christian M. Girgis
wiley   +1 more source

Home - About - Disclaimer - Privacy